NEW ZEALAND GAZETTE, No. 10

2 FEBRUARY 2006

10 tablets or capsules of diphenhydramine theoclate for
the prevention or treatment of motion sickness except
when sold at a transport terminal or aboard a ship or
plane

Diphenylpyraline; for oral use when combined with one or
more other therapeutically active substances for the
treatment of coughs, colds or influenza when at least
one of the other therapeutically active substances is
a sympathomimetic decongestant or in a day/night pack
containing diphenylpyraline in the bedtime dose and in
preparations for adults or children two years of age or
more

Doxylamine; for oral use when combined with one or
more other therapeutically active substances for the
treatment of coughs, colds or influenza when at least
one of the other therapeutically active substances is a
sympathomimetic decongestant or in a day/night pack
containing doxylamine in the bedtime dose and in
preparations for adults or children two years of age or
more

Duboisia leichhardtii; for oral use in liquid form in
medicines containing 0.03% or less and 0.3 milligrams
or less per dose and not more than 1.2 milligrams per
recommended daily dose of total solanaceous alkaloids
or in solid dose form in medicines containing 0.3
milligrams or less per dose form and not more than
1.2 milligrams per recommended daily dose of total
solanaceous alkaloids

Duboisia myoporides; for oral use in liquid form in
medicines containing 0.03% or less and 0.3 milligrams
or less per dose and not more than 1.2 milligrams per
recommended daily dose of total solanaceous alkaloids
or in solid dose form in medicines containing 0.3
milligrams or less per dose form and not more than
1.2 milligrams per recommended daily dose of total
solanaceous alkaloids

Fluorides; for internal use in medicines containing 2.2
milligrams or less per dose form of sodium fluoride; for
external use in medicines other than pastes, gels or
powders for cleaning the teeth containing 2.5% or less;
except in dental hygiene products other than pastes,
gels or powders for cleaning the teeth containing 220
milligrams or less per litre or per kilogram and in packs
containing not more than 120 milligrams of total fluoride

Flurbiprofen; in throat lozenges containing 10 milligrams or
less per lozenge

*Fluticasone; in aqueous nasal sprays delivering up to
50 micrograms per actuation when the maximum
recommended daily dose is not greater than 200
micrograms and the medicine has received the consent of
the Minister or the Director-General to its distribution as
a pharmacy-only medicine

Folic acid; for oral use in medicines containing more than
500 micrograms per recommended daily dose

Folinic acid; for oral use in medicines containing more than
500 micrograms per recommended daily dose

Glyceryl trinitrate; for external use; except in medicines
containing 100 micrograms or less per litre or per
kilogram

Hydroquinone; for external use in medicines containing 2%
or less except in hair preparations containing 1% or less

Hyoscine; for transdermal use in medicines containing
2 milligrams or less of total solanaceous alkaloids per
dose unit; for oral use in liquid form in medicines
containing 0.03% and 0.3 milligrams or less per dose
and not more than 1.2 milligrams per recommended
daily dose or in solid dose form in medicines containing
0.3 milligrams or less per dose unit and not more than

1.2 milligrams per recommended daily dose of total
solanaceous alkaloids

Hyoscyamine; for external use in medicines containing
0.03% or less of total solanaceous alkaloids; for oral
use in liquid form in medicines containing 0.03% and
0.3 milligrams or less per dose and not more than 1.2
milligrams per recommended daily dose or in solid dose
form in medicines containing 0.3 milligrams or less
per dose unit and not more than 1.2 milligrams per
recommended daily dose of total solanaceous alkaloids

Hyoscyamus niger; for oral use in liquid form in medicines
containing 0.03% and 0.3 milligrams or less per dose
and not more than 1.2 milligrams per recommended
daily dose of total solanaceous alkaloids or in solid dose
form in medicines containing 0.3 milligrams or less
per dose unit and not more than 1.2 milligrams per
recommended daily dose except in packs containing
30 micrograms or less of total solanaceous alkaloids

*Ibuprofen; for oral use in liquid form in packs containing
not more than 4 grams in medicines which have received
the consent of the Minister or the Director-General to
their sale as pharmacy-only medicines and which are
sold in the manufacturer’s original pack; for oral use in
solid dose form containing not more than 200 milligrams
per dose form in medicines which have received the
consent of the Minister or the Director-General to their
sale as pharmacy-only medicines and which are sold in
the manufacturer’s original pack; except in packs
containing 200 milligrams or less per oral solid dose
form and not more than 25 dose units per pack when
in medicines which have received the consent of the
Minister or the Director-General to their sale as general
sale medicines and which are sold in the manufacturer’s
original pack

Lignocaine; for external use in medicines containing 10% or
less and more than 2%; for urethral use

Meclozine; in a sealed container of not more than 12 tablets
or capsules for the prevention of travel sickness except
when sold at a transport terminal or aboard a ship or
plane

Mepyramine; for dermal use

Minoxidil; for external use in medicines containing 5% or less

*Mometasone; in aqueous nasal sprays delivering up to
50 micrograms per actuation when the maximum
recommended daily dose is not greater than 200
micrograms and the medicine has received the consent
of the Minister or the Director-General to its distribution
as a pharmacy-only medicine

Naphazoline

Nicotine; for inhalation except when sold from a smoking
cessation clinic run under the auspices of a registered
medical practitioner, nurse, pharmacist or psychologist

*Nizatidine; in medicines which have received the consent
of the Minister or the Director-General to their sale as
pharmacy-only medicines and which are sold in the
manufacturer’s original pack containing not more than
14 days’ supply

Nystatin; for dermal use

Pheniramine; for ophthalmic use; for oral use when
combined with one or more other therapeutically active
substances for the treatment of coughs, colds or
influenza when at least one of the other therapeutically
active substances is a sympathomimetic decongestant or
in a day/night pack containing pheniramine in the
bedtime dose and in preparations for adults or children
two years of age or more

Phenylephrine; for nasal use in medicines containing more
than 1%; for ophthalmic use in medicines containing